1. Introduction {#sec1}
===============

Head and neck oncological patients suffer from various functional, physical, and emotional impairments due to both the primary illness and the secondary consequences of the tumor treatment \[[@B1]\]. The oncological treatment of head and neck tumors depends on the location and the stage of the tumor, as well as the treatment preferences of the individual patient. Head and neck oncological treatment can include surgery, radiotherapy, chemotherapy, or combinations of these. The impact of head and neck oncological treatments on the anatomical structures, organ function, and the quality of life (QoL) should not be underestimated \[[@B2]\]. For instance, the implications of loss of function for people treated nonsurgically for head and neck cancer (HNC) and its detrimental effects on functioning and QoL are well documented \[[@B3]\].

In order to assist people with dysphagia to adjust to and live successfully with the sequelae of the primary condition, speech pathologists managing this caseload need to ensure posttreatment services are available \[[@B4]\] that address not only the physical but also the emotional and psychosocial needs. A qualitative study by Nund et al. \[[@B5]\] exploring dysphagia management by speech pathologists suggests that care givers generally feel ill-prepared for their role. Furthermore, this study suggests that clinicians should provide adequate and timely training and support to carers. Furthermore, Krisciunas et al. \[[@B6]\] concluded that within speech pathology there is no standardised therapy for HNC patients and scant evidence to support any particular protocol. As a result, institutions and individual speech pathologists need to develop their own protocols based on "standard" practices or anecdotal evidence.

Evidence-based practice (EBP) is hailed to be paramount in the practice of speech pathology \[[@B7]\]. The American Speech-Language-Hearing Association (ASHA) defines evidence-based practice as "...an approach in which current, high-quality research evidence is integrated with practitioner expertise and client preferences and values, into the process of making clinical decisions" \[[@B8]\]. Essentially, EBP involves moving the foundation for clinical decisions from clinical protocols centered solely on expert opinion to the integration of clinical expertise, the best current research evidence, and individual client values. To facilitate EBP in healthcare, clinical practice guidelines can be developed to summarise clinically relevant evidence \[[@B9]\].

Several reviews have been published about the outcomes after radiotherapy and/or chemotherapy in HNC patients (e.g., Frowen and Perry \[[@B10]\]; Jacobi et al. \[[@B11]\]; van der Molen et al. \[[@B12]\]; Paleri et al. \[[@B13]\]; Roe et al. \[[@B14]\]). Most of the reviews focused on selected functional domains in populations with HNC: health-related QoL \[[@B15]\], swallowing \[[@B13], [@B14], [@B16]\], and voice and speech \[[@B11]\]. Only the review by van der Molen et al. \[[@B12]\] covered a wider range of functional outcomes in patients with advanced HNC, including swallowing, mouth opening, nutrition, pain, and QoL. Further, the purpose of some studies was to provide evidence-based clinical guidelines (e.g., Paleri et al. \[[@B13]\]) and they did not perform systematic literature searches in line with the PRISMA guidelines \[[@B17]\]. As such, even though a number of reviews have been published over the last ten years, a comprehensive updated systematic review is needed that includes all functional domains affected by radiotherapy and/or chemotherapy in patients with head and neck carcinoma.

A systematic review was conducted to describe the effects of radiotherapy and/or chemotherapy on functions of the upper aerodigestive tract in patients with HNC and examined the evidence of interventions by speech pathologists.

2. Methods {#sec2}
==========

A systematic literature search was performed by two independent reviewers. The electronic biomedical databases PubMed and Embase were used (search period from start of database until 5 May 2016). The searches were limited to English language publications. In PubMed the MeSH terms*larynx* or*hypopharynx* were combined with all MeSH terms related to head and neck neoplasms ([Table 1](#tab1){ref-type="table"}). Next, the results were linked to all MeSH terms for chemotherapy or radiotherapy, after which the outcome was combined with all MeSH terms found for dysfunctions of the upper aerodigestive tract and limited with adults +19 years. The exact syntax of the literature search is presented in [Table 1](#tab1){ref-type="table"}.

In Embase the thesaurus terms*larynx* or*hypopharynx* were linked to*neoplasm* and*radiotherapy* or*chemotherapy*. Next, the search outcome was combined with the following terms:*dysphagia*,*speech*,*speech disorder*,*voice*,*dysphonia*,*xerostomia*,*quality of life*,*dysarthria, or trismus* (see [Table 1](#tab1){ref-type="table"}).

To identify the most recent publications, the search was complemented by free text words in PubMed and Embase (for the period after April 2015 until May 2016). Truncation symbols and wildcards were used to search for variant forms of words or word extensions:*Laryn* ^*∗*^,*pharyn* ^*∗*^ or*hypopharyn* ^*∗*^ were combined with*cancer* ^*∗*^,*neoplasm* ^*∗*^,*tumour* ^*∗*^ or*carcinoma* ^*∗*^. Furthermore, these free text words were combined with*radiation* ^*∗*^,*radiotherap* ^*∗*^,*chemotherap* ^*∗*^,*adjuvant therap* ^*∗*^ or*radiochemotherap* ^*∗*^ and, finally, combined with*deglut* ^*∗*^,*swallow* ^*∗*^,*dysphag* ^*∗*^,*speech* ^*∗*^,*voic* ^*∗*^,*articulat* ^*∗*^,*dysphon* ^*∗*^,*quality of life* ^*∗*^,*xerostom* ^*∗*^,*dysarthr* ^*∗*^ or*anarthr* ^*∗*^.

Only articles presenting both pre- and postintervention data of the upper aerodigestive tract functions of the participants were included. Review articles and studies with a population sample of less than 20 patients were excluded, as well as experiments on animals or articles not published in English. Furthermore, studies published before 1990, case reports, expert opinions, and articles describing combinations of therapy including surgical interventions were excluded.

Final decisions on inclusion were made based on the original articles by consensus between two expert reviewers in accordance with the PRISMA statement \[[@B17]\]. The reference lists of all the included articles were searched for additional literature. Next, the standard quality assessment QualSyst as described by Kmet et al. \[[@B18]\] was performed in order to evaluate the methodological strength and weaknesses of the included studies. All ratings were performed by two independent reviewers. After consensus, studies with poor methodology scores (\<50%) were excluded. All included articles were classified according to the Australian National Health and Medical Research Council (NHMRC) Evidence Hierarchy \[[@B19]\]. Data were retrieved from all studies and tabulated; further details on selected speech pathology interventions were summarised separately.

3. Results {#sec3}
==========

Using MeSH or thesaurus terms, 304 articles were located in PubMed and 201 in Embase. Free text word searches resulted in another 148 articles in PubMed and 397 in Embase. The combination of these searches, without overlap, yielded 947 articles. [Figure 1](#fig1){ref-type="fig"} outlines the PRISMA reviewing process according to Moher et al. \[[@B20]\]. Sixty articles met all inclusion criteria.

[Table 2](#tab2){ref-type="table"} shows the outcomes of the QualSyst critical appraisal tool by Kmet et al. \[[@B18]\]. As all studies had sufficient methodological quality, no further studies were excluded; the overall methodological quality ranged from adequate to good with 0 studies ranked as poor, 3 studies as adequate, 3 studies as good, and 54 studies as strong. Based on the NHMRC Evidence Hierarchy \[[@B19]\], 6 studies were classified as level II evidence and 54 studies as level III evidence.

All 60 studies focused on different functions of the upper aerodigestive tract following radiotherapy and/or chemotherapy for HNC. The following constructs were evaluated across the different studies: communication (voice and speech), functions of the digestive tract (oral intake, weight loss, dysphagia, trismus, xerostomia, and tube dependency), QoL, and overall survival rates.

[Table 3](#tab3){ref-type="table"} provides a summary of the 60 retrieved observational and intervention studies that met the inclusion criteria. The first column presents the reference of the author(s). The second column represents the number of subjects, the third column represents the etiology of the head and neck malignancies, and the 4th column displays the staging of the malignancies. The 5th column shows whether voice and/or speech, digestive tract, and QoL were studied. The 6th and 7th columns show the evaluation techniques and the treatment, respectively. The 8th column presents the follow-up and the last column describes the author\'s key findings.

3.1. Voice and/or Speech Function {#sec3.1}
---------------------------------

Twenty-four studies evaluated voice and/or speech function \[[@B24]--[@B43]\] with a follow-up time ranging from 1-month follow-up \[[@B42]\] to ten-year follow-up \[[@B43]\]. Most studies included patients with laryngeal tumors only; however 11 studies \[[@B25], [@B30], [@B22], [@B31], [@B34]--[@B37], [@B44]\] also included nonlaryngeal tumors. Seventeen studies \[[@B24], [@B26], [@B28], [@B29], [@B21], [@B31]--[@B33], [@B35]--[@B38], [@B39]--[@B43]\] included patients with low-grade tumors (i.e., T1 and T2) and 15 studies included patient with advanced tumors \[[@B25], [@B27], [@B30], [@B22]--[@B37], [@B23], [@B42], [@B44]\].

Nine studies \[[@B26], [@B21], [@B31], [@B33], [@B34], [@B36], [@B39], [@B42], [@B44]\] used acoustic analysis to evaluate voice quality, six studies \[[@B27]--[@B29], [@B35], [@B36], [@B40]\] used the Voice Handicap Index, and three studies \[[@B24], [@B39], [@B43]\] used videolaryngostroboscopy. In several studies, either descriptions of how voice quality was evaluated were missing or nonvalidated tools were used (e.g., patients self-reporting or trial-specific questionnaires). Only four studies \[[@B26], [@B32], [@B23], [@B44]\] reported whether the patient received any voice therapy.

All the studies reported good to excellent outcomes for voice quality at long-term follow-up. Some studies specifically reported pre- to posttreatment improvements of voice or speech quality following radiotherapy and/or chemotherapy \[[@B25], [@B26], [@B21]\]. However, other studies \[[@B38], [@B23], [@B42], [@B44]\] reported a deterioration after therapy at long-term follow-up. Al-Mamgani et al. \[[@B29]\] found a better voice outcome in case of single vocal cord irradiation compared with irradiation of the whole larynx. Mittal et al. \[[@B37]\] concluded that radiation with tissue/dose compensation (TDC) improved articulatory outcome compared to radiation without TDC.

3.2. Functions of the Digestive Tract {#sec3.2}
-------------------------------------

Forty studies \[[@B16], [@B25], [@B22], [@B35]--[@B37], [@B42], [@B45]--[@B73]\] describe the effects of radiotherapy and/or chemotherapy on the functions of the digestive tract and used a variety of outcome measures. Of these 40 studies, 16 studies \[[@B16], [@B36], [@B37], [@B45], [@B49], [@B52], [@B53], [@B55], [@B57], [@B61], [@B63], [@B65], [@B67], [@B68], [@B76], [@B71]\] used videofluoroscopy to measure physiological changes in swallowing function. Eight studies \[[@B22], [@B36], [@B46], [@B47], [@B49], [@B54], [@B58], [@B72]\] used feeding tube dependency as a (dichotomous) outcome, whereas seven studies \[[@B36], [@B46], [@B56], [@B63], [@B64], [@B67], [@B76]\] described the level of oral intake in more detail. Only four studies \[[@B36], [@B38], [@B55], [@B73]\] used a condition specific validated measure for swallowing disorders (e.g., MDADI).

With regard to nutritional status, five studies \[[@B22], [@B58], [@B60], [@B61], [@B76]\] used the body mass index as an outcome or reported specifically on weight gain or loss. Seven studies \[[@B36], [@B38], [@B48], [@B51], [@B62], [@B76], [@B71]\] used the presence of trismus as an outcome by reporting on the maximum distance of mouth opening. Saliva flow (as a measure of xerostomia) was used in four studies \[[@B38], [@B37], [@B66], [@B69]\].

Follow-up times in these studies range from immediately after therapy \[[@B60]\] to 6 years after therapy \[[@B36]\], describing both low stage tumors and more advanced tumors. Thirty-two studies used the TNM-classification system, stage was described in six other studies, and the remaining two studies did not report on tumor stage or grade. However, it was unclear whether the clinical TNM-score or the pathological TNM-score was used to describe the severity of the disease. Eight studies \[[@B16], [@B36], [@B46], [@B48], [@B51], [@B55], [@B56], [@B67], [@B76], [@B71]\] described whether the patients received functional treatment (by a speech pathologist); the remainder of the articles did not mention whether the patient received any additional treatment.

Nine studies reported impaired swallowing function following radiotherapy and/or chemotherapy \[[@B38], [@B45], [@B50], [@B53]--[@B55], [@B67], [@B72], [@B73]\].

Five studies \[[@B16], [@B74], [@B75], [@B59], [@B64]\] showed that swallowing was least affected at baseline, worst immediately following posttreatment (0--3 months after treatment), and improved by 6--12 months after treatment and later. However, swallowing usually did not return to pretreatment functioning level. In four studies \[[@B49], [@B52], [@B57], [@B71]\], a relation between dose-volume, dysphagia, and aspiration was found. Caudell et al. \[[@B49]\] showed that a mean radiation dosage \>41 Gy with \>24% volume of the larynx being radiated was associated with increased percutaneous endoscopic gastrostomy (PEG) dependency and aspiration. Akst et al. \[[@B46]\] correlated advanced tumor stage and age \>60 years with a deterioration of swallowing.

Ackerstaff et al. \[[@B25]\] demonstrated improved oral intake postradiotherapy and/or chemotherapy. Stenson et al. \[[@B68]\] stated that weight remained unchanged after treatment (via oral route), whereas Nourissat et al. \[[@B60]\] described a mean weight loss of 2.2 kg posttreatment.

3.3. QoL {#sec3.3}
--------

Twenty-five studies \[[@B25], [@B27], [@B28], [@B30]--[@B22], [@B32], [@B33], [@B36], [@B38], [@B42], [@B44], [@B47], [@B74], [@B52], [@B54], [@B75], [@B60], [@B62], [@B66], [@B70], [@B73]--[@B79]\] described the short- and long-term effects of treatment for HNC on patients\' general QoL. The European Organization for Research and Treatment of Cancer (EORTC) C30-questionnaire was used in fifteen studies \[[@B25], [@B27], [@B28], [@B30], [@B32], [@B33], [@B36], [@B42], [@B47], [@B54], [@B60], [@B62], [@B77]--[@B79]\] and the more HNC specific EORTC H&N35 was used in thirteen studies \[[@B25], [@B27], [@B28], [@B32], [@B33], [@B36], [@B38], [@B42], [@B47], [@B62], [@B77]--[@B79]\]. Other questionnaires that were used included the University of Washington QoL Questionnaire (UWQoL) \[[@B52], [@B66], [@B70], [@B73]\], the Head and Neck QoL or HNQoL \[[@B52], [@B70]\], and the Xerostomia related QoL or XQoL \[[@B66], [@B70]\]. Follow-up time for QoL was up to six years after treatment \[[@B36]\], including patients with tumors that were early staged and patients with advanced tumors.

Although three studies \[[@B21], [@B70], [@B77]\] demonstrated improvements in QoL, four studies \[[@B25], [@B38], [@B42], [@B53]\] reported a decrease in general QoL as a result of radiotherapy and/or chemotherapy. Bansal et al. \[[@B30]\] found a significant decline in physical, social, and emotional functioning as well as in global health scores following a course of radiotherapy. However, the patients\' functional scores improved one month after treatment but did not reach pretreatment levels. The health-related QoL (HRQoL) scores of the majority of patients in the Bottomley et al. \[[@B78]\] study returned to baseline at 48-month follow-up. These findings support the findings of Ackerstaff et al. \[[@B25]\], Cohen et al. \[[@B74]\], Karlsson et al. \[[@B33]\], List et al. \[[@B75]\], and Wilson et al. \[[@B73]\], who suggested that HRQoL deteriorates significantly immediately after treatment, with variable degrees of improvement 3--72 months after treatment.

3.4. Reported (Efficacy of) Speech Pathology Interventions {#sec3.4}
----------------------------------------------------------

We assessed the speech pathology interventions against the following criteria: (a) whether a detailed description of the intervention was provided; (b) whether the authors provided a description of treatment duration and intensity; and (c) what the speech pathology intervention outcomes were. The reported efficacy of 14 speech pathology intervention studies aimed at addressing problems in dysphagia, speech, voice, and trismus is summarised in [Table 4](#tab4){ref-type="table"}.

Of the 60 articles included in this review, 14 studies \[[@B16], [@B26], [@B22], [@B32], [@B36], [@B23], [@B44], [@B46], [@B48], [@B55], [@B56], [@B67], [@B76], [@B71]\] reported whether there was any treatment for the sequelae of radiotherapy and/or chemotherapy. Of these intervention studies, five focused on voice-related problems \[[@B26], [@B32], [@B36], [@B23], [@B44]\], two focused on trismus \[[@B48], [@B51]\], seven focused on swallowing disorders \[[@B16], [@B36], [@B46], [@B55], [@B56], [@B67], [@B76]\], and one study reported on both swallowing disorders and trismus \[[@B71]\].

The three studies that investigated the treatment of trismus \[[@B48], [@B51], [@B71]\] presented the most detailed information on what the interventions involved. The study by Dijkstra et al. \[[@B51]\] described a wide variety of trismus-specific therapies, suggesting that most patients received a combination of therapies. The patients in the van der Molen et al. \[[@B44]\] and Kraaijenga et al. \[[@B36]\] studies did not receive any speech therapy. The remainder of the studies reported that patients received speech therapy; however, most of these studies did not provide specific data on treatment duration or intensity. None of the voice-related studies provided information on the specific exercises prescribed to patients except Karlsson et al. \[[@B32]\].

Of the eight studies on swallowing disorders, only Kotz et al. \[[@B56]\] and van der Molen et al. \[[@B76]\] described the prescribed exercises in detail. The aim of the latter study was to compare the effectiveness of experimental rehabilitation to standard rehabilitation in 49 advanced HNC patients. The authors concluded that preventive rehabilitation is feasible and effective in reducing the extent and/or severity of various functional short-term effects of chemoradiotherapy \[[@B71]\]. This finding is supported by the 6-year follow-up study by Kraaijenga et al. \[[@B36]\]. Kotz et al. \[[@B56]\] described a temporary improvement. These are the only studies that provided detailed information about the speech pathology intervention and reported on the effectiveness of the intervention.

4. Discussion {#sec4}
=============

In total, 60 studies met the inclusion criteria. The studies described the effects of radiotherapy and/or chemotherapy on the functions of the upper aerodigestive tract in patients with HNC. The articles yielded by this systematic review vary in their findings regarding tumor characteristics and treatment modalities. As a result of this variability, no statistical pooling was possible. We also set out to investigate the involvement of speech pathologists in treating patients with HNC.

When considering treatment outcomes, voice quality worsened at the start of radiotherapy and/or chemotherapy but eventually improved after therapy finished. Dysphagia can be a major side effect of HNC and its treatment. The high incidence of dysphagia in this study population can cause serious secondary consequences, such as malnutrition, dehydration, an increased risk of aspiration, and, at worst, death \[[@B80]\]. As dysphagia is a common sequela to oncological treatment, early detection and treatment are needed to avoid or minimise serious secondary complications \[[@B81]\].

The general description of the study population in [Table 3](#tab3){ref-type="table"} shows that there was great variability in both the location of the tumor and the grading/staging, making comparisons of these studies difficult. As the follow-up times varied in each study, the outcomes may be noncomparable. Thus, this review shows that there is a need for more standardised approaches to research in this field.

Additionally, a large range of outcome measures were used, some of which are not validated. This calls into question the reliability of results reported in some of the studies. The use of validated and standardised assessments in future research would provide more robust findings.

When considering the functional outcomes of radiotherapy and/or chemotherapy, one of the most important factors is whether the patient had received voice or swallowing therapy. Interestingly, only 14 of the 60 included studies reported whether the patients received any speech therapy. Thus, in 46 articles functional results, such as voice quality, are presented with no specification of whether the patient received therapy. As some of these studies have a follow-up of \>2 years, it is fair to assume that patients sought help for voice or swallowing problems. Therefore, the involvement of speech therapy may be underreported, suggesting that the presented outcomes in these studies are biased and raise questions about their reliability.

When information was provided about treatment, only six articles \[[@B32], [@B48], [@B51], [@B56], [@B76], [@B71]\] described in detail the treatment intensity as the actual treatment. Furthermore, these studies are the only five that include conclusions about the efficacy of speech therapy in this specific population. In the context of EBP, this finding demonstrates the need for more research into the efficacy of speech pathology interventions for patients with HNC receiving radiotherapy and/or chemotherapy.

To enable the objective reporting of the effectiveness of radiation and/or chemotherapy, baseline measurements of different aspects of voice quality and swallowing are required. To manage expectations, healthcare professionals and patients need to be made aware that some aspects of both voice and swallowing commonly do not recover to the level prior to the oncological intervention \[[@B16]\]. Regarding effectiveness of voice treatments, the following multidimensional assessment is recommended \[[@B82]\]: a videolaryngostroboscopy recording of the laryngeal structures and the vocal fold vibration; an acoustic and a perceptual analysis of voice; a voice-related questionnaire on QoL (e.g., the Voice Handicap Index) \[[@B83]\]; and a functional health status questionnaire. Such a protocol would be in line with the recommendations for functional assessment of voice pathology as described by the Committee on Phoniatrics of the European Laryngological Society \[[@B84]\].

When describing aspects of swallowing function, both fiber optic endoscopic evaluation of swallowing and videofluoroscopy are considered to be the gold standard in dysphagia assessment \[[@B85]\]. In addition to these tools, questionnaires on HRQoL and functional health status are recommended and should be integrated in the overall swallowing assessment protocol. Repeated measurements of outcome measures should be performed in order to monitor any side effects of the oncological intervention, to detect spontaneous recovery, and to measure the effects of the speech pathology interventions. Apart from baseline measurements, posttreatment and follow-up measurements should be used to monitor functional and QoL outcomes.

Additional research is needed to develop clinical practice guidelines to support evidence-based practice in the area of dysphagia, speech, voice, and trismus following radiotherapy and/or chemotherapy in patients with head and neck carcinoma. These practice guidelines should bring together the best available current evidence within a specific clinical area, formulating evidence-based recommendations for clinicians and present choices between different interventions that have an impact on health and use of resources \[[@B86]\]. This systematic review summarised the effects of radiotherapy and/or chemotherapy on the function of the upper aerodigestive tract in patients with head and neck cancer. However, because of the marked variation in treatment protocols and patient characteristics, outcome data from the included studies cannot be easily generalised. Recommendations for future studies advocate the use of a multidimensional assessment protocol, using well-validated measures and standardised pretreatment, posttreatment, and follow-up measurements, thus allowing for future meta-analysis of homogeneous outcomes.

5. Conclusion {#sec5}
=============

The studies included in this systematic review described a wide variety of outcomes in patients with HNC following radiotherapy and/or chemotherapy. The findings about the long-term functional implications of radiotherapy and/or chemotherapy in patients with HNC are inconclusive as a result of the wide range of outcome measures used and the possible influence of underreported speech therapy.

Future researchers need to consider targeting more homogeneous groups using standardised treatment protocols to improve the treatment outcomes, thereby decreasing the side effects of the oncological treatments. Findings of these studies need to inform the decision-making process in the treatment of HNC so complications can be better predicted with due consideration of the possible negative side effects to the upper aerodigestive tract. Although the main objective of most studies was to determine curing rates, the importance of the functional implications of the side effects of oncology treatments should not be overlooked, particularly their impact on QoL. Finally, more research is needed to gain a full understanding of the complexity and variety in the effects of radiotherapy and/or chemotherapy on the functions of the upper aerodigestive tract following HNC.
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###### 

Methodological quality based on QualSyst critical appraisal tool by Kmet et al. 2004 \[[@B18]\] and NHMRC 1999 \[[@B19]\] evidence level of included articles.

  Reference                                  Kmet score (%)   Methodological quality^1^   NHMRC level of evidence^2^
  ------------------------------------------ ---------------- --------------------------- ----------------------------
  Aaltonen et al. 2014 \[[@B24]\]            25/28 (89%)      Strong                      II
  Ackerstaff et al. 2009 \[[@B25]\]          22/28 (79%)      Good                        II
  Agarwal et al. 2009 \[[@B26]\]             19/24 (79%)      Good                        III-2
  Agarwal et al. 2011 \[[@B45]\]             17/20 (85%)      Strong                      III-3
  Akst et al. 2004 \[[@B46]\]                17/20 (85%)      Strong                      III-3
  Al-Mamgani et al. 2012 \[[@B27]\]          19/20 (95%)      Strong                      III-3
  Al-Mamgani et al. 2012 \[[@B47]\]          21/22 (95%)      Strong                      III-3
  Al-Mamgani et al. 2013 \[[@B28]\]          21/22 (95%)      Strong                      III-3
  Al-Mamgani et al. 2015 \[[@B29]\]          21/22 (95%)      Strong                      III-3
  Bansal et al. 2004 \[[@B30]\]              14/24 (58%)      Adequate                    III-3
  Bibby et al. 2008 \[[@B21]\]               18/22 (82%)      Strong                      III-2
  Bottomley et al. 2014 \[[@B78]\]           24/28 (86%)      Strong                      II
  Buchbinder et al. 1993 \[[@B48]\]          14/26 (54%)      Adequate                    III-1
  Caudell et al. 2010 \[[@B49]\]             21/22 (95%)      Strong                      III-3
  Christianen et al. 2015 \[[@B50]\]         21/22 (95%)      Strong                      III-3
  Cohen et al. 2006 \[[@B74]\]               19/20 (95%)      Strong                      III-3
  Dornfeld et al. 2007 \[[@B22]\]            17/22 (77%)      Strong                      III-3
  Dijkstra et al. 2007 \[[@B51]\]            19/22 (86%)      Strong                      III-3
  Feng et al. 2007 \[[@B52]\]                19/22 (86%)      Strong                      III-3
  Feng et al. 2010 \[[@B53]\]                20/20 (100%)     Strong                      III-3
  Frowen et al. 2010 \[[@B16]\]              22/22 (100%)     Strong                      III-2
  Haderlein et al. 2014 \[[@B54]\]           17/20 (85%)      Strong                      III-3
  Hutcheson et al. 2014 \[[@B55]\]           18/20 (90%)      Strong                      III-3
  Jacobi et al. 2016 \[[@B31]\]              17/18 (94%)      Strong                      III-3
  Karlsson et al. 2015 \[[@B32]\]            26/28 (93%)      Strong                      II
  Karlsson et al. 2016 \[[@B33]\]            18/20 (90%)      Strong                      III-3
  Kazi et al. 2008 \[[@B34]\]                17/20 (85%)      Strong                      III-2
  Kerr et al. 2015 \[[@B35]\]                19/20 (95%)      Strong                      III-2
  Kotz et al. 2012 \[[@B56]\]                24/28 (86%)      Strong                      II
  Kraaijenga et al. 2014 \[[@B36]\]          19/20 (95%)      Strong                      III-3
  Kumar et al. 2014 \[[@B57]\]               19/20 (95%)      Strong                      III-2
  Lazarus et al. 2014 \[[@B38]\]             19/20 (95%)      Strong                      III-3
  List et al. 1999 \[[@B75]\]                15/18 (83%)      Strong                      III-3
  McLaughlin et al. 2010 \[[@B58]\]          19/20 (95%)      Strong                      III-3
  Mittal et al. 2001 \[[@B37]\]              16/20 (80%)      Strong                      III-3
  Murry et al. 1998 \[[@B59]\]               11/20 (55%)      Adequate                    III-3
  Niedzielska et al. 2010 \[[@B39]\]         17/20 (85%)      Strong                      III-2
  Nourissat et al. 2010 \[[@B60]\]           23/26 (88%)      Strong                      III-3
  Ottoson et al. 2014 \[[@B61]\]             19/22 (86%)      Strong                      III-3
  Pauli et al. 2013 \[[@B62]\]               19/22 (86%)      Strong                      III-3
  Pauloski et al. 2006 \[[@B63]\]            18/20 (90%)      Strong                      III-3
  Rademaker et al. 2003 \[[@B64]\]           17/20 (85%)      Strong                      III-3
  Remmelts et al. 2013 \[[@B40]\]            18/20 (90%)      Strong                      III-3
  Salama et al. 2008 \[[@B65]\]              17/20 (85%)      Strong                      III-3
  Sanguineti et al. 2014 \[[@B23]\]          19/20 (95%)      Strong                      III-3
  Scrimger et al. 2007 \[[@B66]\]            18/20 (90%)      Strong                      III-3
  Spector et al. 1999 \[[@B41]\]             17/22 (77%)      Good                        III-3
  Starmer et al. 2014 \[[@B67]\]             18/20 (90%)      Strong                      III-3
  Stenson et al. 2010 \[[@B68]\]             16/20 (80%)      Strong                      III-3
  Strigari et al. 2010 \[[@B69]\]            17/20 (85%)      Strong                      III-3
  Tuomi et al. 2015 \[[@B42]\]               18/20 (90%)      Strong                      III-2
  Urdaniz et al. 2005 \[[@B77]\]             18/20 (90%)      Strong                      III-2
  Vainshtein et al. 2015 \[[@B70]\]          20/24 (83%)      Strong                      III-3
  van der Molen et al. 2011 \[[@B76]\]       24/26 (92%)      Strong                      II
  van der Molen et al. 2012 \[[@B44]\]       16/20 (80%)      Strong                      III-3
  van der Molen et al. 2013 \[[@B71]\]       19/20 (95%)      Strong                      III-3
  Verdonck-de Leeuw et al. 1999 \[[@B43]\]   18/20 (90%)      Strong                      III-2
  Verdonck-de Leeuw et al. 2014 \[[@B79]\]   16/20 (80%)      Strong                      III-2
  Vlacich et al. 2014 \[[@B72]\]             18/20 (90%)      Strong                      III-3
  Wilson et al. 2011 \[[@B73]\]              18/20 (90%)      Strong                      III-3

^1^Methodological quality: strong \> 80%; good 60--79%; adequate 50--59%; poor \< 50%.

^2^NHMRC evidence hierarchy designates the following hierarchy: level I (evidence obtained from a systematic review of all relevant RCTs), level II (evidence obtained from at least one properly designed RCT), level III-1 (evidence obtained from well-designed pseudo-RCTs \[alternate allocation or some other method\]), level III-2 (evidence obtained from comparative studies with concurrent controls and allocation not randomised \[cohort studies\], case control studies, or interrupted time series with a control group), level III-3 (evidence obtained from comparative studies with historical control, two or more single-arm studies, or interrupted time series without a parallel control group), and level IV (evidence obtained from case series, either posttest or pretest and posttest).

###### 

Overview of included observational and intervention studies (*N* = 60) that met eligibility criteria.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                         Subjects     Carcinoma                                             Staging                  Topic   Evaluation technique                                                                                                   Treatment(s)                                                              Follow-up                                       Key findings/author\'s conclusions
  --------------------------------- ------------ ----------------------------------------------------- ------------------------ ------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Aaltonen et al. 2014 \[[@B24]\]   *N* = 56     Glottic = 56 (100%)                                   T1a = 56 (100%)          V       Videolaryngostroboscopy\                                                                                               Group 1: laser surgery (*n* = 31)\                                        6, 24 months                                    Similar overall voice quality for both groups. Laser surgery yielded more breathiness compared to RT
                                                                                                                                        Expert rating (GRBAS)\                                                                                                 Group 2: RT (*n* = 25)                                                                                                    
                                                                                                                                        Patient self-rating (VAS) hoarseness and impact on everyday life                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                         

  Ackerstaff et al.\                *N* = 207    Oral cavity = 40 (19%)\                               T3 = 65 (31%)\           V\      EORTC QLQ-C30\                                                                                                         Group 1: intra-arterial cisplatin 4 weekly (*n* = 104) + RT\              7 weeks; 3 months; 1, 2, 5 years                Both groups showed improved oral intake and voice quality, at 1-year follow-up often better compared to baseline
  2009 \[[@B25]\]                                Oropharyngeal = 129 (62%)\                            T4 = 142 (69%)           D\      EORTC QLQ-H&N35\                                                                                                       Group 2: intravenous cisplatin 3 weekly (*n* = 103) + RT                                                                  
                                                 Hypopharyngeal = 38 (19%)                                                      QoL     Trial-specific questionnaires                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                         

  Agarwal et al.\                   *N* = 50     Glottic = 50 (100%)                                   T1 = 33 (66%)\           V       Voice analysis\                                                                                                        RT                                                                        3--6 months                                     A trend for improvement in voice quality following RT was found
  2009 \[[@B26]\]                                                                                      T2 = 17 (34%)                    Acoustic parameters: frequency, intensity, perturbation\                                                                                                                                                                                         
                                                                                                                                        Patient-reported improvement in voice quality                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                         

  Agarwal et al.\                   *N* = 47     Oropharyngeal\                                        T1\                      D       Videofluoroscopy\                                                                                                      CRT                                                                       2, 6, 12 months                                 Significant impairment of swallowing was found: most frequently residue and aspiration
  2011 \[[@B45]\]                                Hypopharyngeal\                                       T2\                              PSS-HN                                                                                                                                                                                                                                           
                                                 Laryngeal\                                            T3\                                                                                                                                                                                                                                                                               
                                                 (No details provided)                                 T4\                                                                                                                                                                                                                                                                               
                                                                                                       (No details provided)                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                         

  Akst et al.\                      *N* = 196    Oral cavity = 12 (6%)\                                T1 = 15 (8%)\            D       Presence of feeding tube\                                                                                              CRT                                                                       3, 6, 12, 24 months                             A majority of patients did not need a tracheotomy but need a feeding tube during treatment. At 1-year follow-up most patients had a (nearly) normal oral intake. Patients with tumor stage IV and age ≥ 60 had prolonged feeding tube use and slower recovery
  2004 \[[@B46]\]                                Base of tongue = 41 (21%)\                            T2 = 42 (21%)\                   Presence of tracheotomy\                                                                                                                                                                                                                         
                                                 Tonsil = 41 (21%)\                                    T3 = 65 (33%)\                   Level of oral diet                                                                                                                                                                                                                               
                                                 Other oropharyngeal =\                                T4 = 70 (36%)\                                                                                                                                                                                                                                                                    
                                                 15 (8%)\                                              Unknown = 4 (2%)                                                                                                                                                                                                                                                                  
                                                 Hypopharyngeal = 34 (17%)\                                                                                                                                                                                                                                                                                                              
                                                 Laryngeal = 50 (26%)\                                                                                                                                                                                                                                                                                                                   
                                                 Unknown = 3 (1%)                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                         

  Al-Mamgani et al.\                *N* = 170    Supraglottic = 121 (71%)\                             T3 = 170 (100%)          V\      EORTC QLQ-C30\                                                                                                         Group 1: CRT (*n* = 48)\                                                  2, 4, 6 weeks; 3, 6, 12 months                  Adding chemotherapy to RT did not diminish QoL or voice handicap
  2012 \[[@B27]\]                                Glottic = 49 (29%)                                                             QoL     EORTC QLQ-H&N35\                                                                                                       Group 2: RT (*n* = 122)                                                                                                   
                                                                                                                                        VHI                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                         

  Al-Mamgani et al.\                *N* = 176    Hypopharyngeal = 176 (100%)                           T1 = 18 (10%)\           D\      Tube dependency\                                                                                                       Group 1: CRT (*n* = 102)\                                                 2, 4, 6 weeks; 3, 6 months; 1, 2 years          CRT significantly improved functional outcome. Acute toxicity increased but late radiation side effects did not increase
  2012 \[[@B47]\]                                                                                      T2 = 55 (31%)\           QoL     EORTC QLQ-C30\                                                                                                         Group 2: RT (*n* = 74)                                                                                                    
                                                                                                       T3 = 56 (32%)\                   EORTC QLQ-H&N35                                                                                                                                                                                                                                  
                                                                                                       T4a = 35 (20%)\                                                                                                                                                                                                                                                                   
                                                                                                       T4b = 12 (7%)                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                         

  Al-Mamgani et al.\                *N* = 1050   Glottic = 1050 (100%)                                 T1a = 551 (52%)\         V\      EORTC QLQ-C30\                                                                                                         RT                                                                        4, 6 weeks; 3, 6, 12, 18, 24, 36, 48 months     Excellent outcome with good QoL and VHI scores
  2013 \[[@B28]\]                                                                                      T1b = 168 (16%)\         QoL     EORTC QLQ-H&N35\                                                                                                                                                                                                                                 
                                                                                                       T2a = 209 (20%)\                 VHI                                                                                                                                                                                                                                              
                                                                                                       T2b = 122 (12%)                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                         

  Al-Mamgani et al.\                *N* = 30     Glottic = 30 (100%)                                   T1a = 30 (100%)          V       Laryngoscopy\                                                                                                          Single vocal cord RT                                                      4, 6, 12 weeks; 6, 12, 18 months                Single vocal cord RT showed better voice quality compared to whole larynx RT
  2015 \[[@B29]\]                                                                                                                       VHI                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                         

  Bansal et al.\                    *N* = 45     Base of tongue = 20 (44%)\                            Stage III = 17 (38%)\    V\      Acute and late morbidity scoring of skin, oropharyngeal mucosa, salivary glands, larynx, and oesophagus (LENT/SOMA)\   RT                                                                        1, 4 months                                     During RT a decline in all QoL domains was found. QoL improved after 1 month but did not reach pre-RT levels
  2004 \[[@B30]\]                                Tonsil = 10 (22%)\                                    Stage IV = 23 (51%)\     QoL     EORTC QLQ-C30                                                                                                                                                                                                                                    
                                                 Unknown = 15 (33%)                                    Not reported = 5 (11%)                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                         

  Bibby et al.\                     *N* = 30     Glottic = 30 (100%)                                   T1 = 21 (70%)\           V\      Voice analysis\                                                                                                        RT                                                                        3, 6, 12 months                                 After RT expert-rated perceptual auditory outcomes, patient self-rated VAS and all subscales of VR-QoL showed significant improvement
  2008 \[[@B21]\]                                                                                      T2 = 9 (30%)             QoL     Patient self-rating voice quality\                                                                                                                                                                                                               
                                                                                                                                        VR-QoL                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                         

  Bottomley et al.\                 *N* = 450    Laryngeal\                                            T2\                      QoL     EORTC QLQ-C30\                                                                                                         Group 1: sequential CRT (*n* = 224)\                                      6, 12, 18, 24, 36, 48 months                    The HRQoL scores of the majority of patients returned to baseline after therapy. No group differences were found
  2014 \[[@B78]\]                                Hypopharyngeal\                                       T3\                              EORTC QLQ-H&N35                                                                                                        Group 2: alternating CRT (*n* = 226)                                                                                      
                                                 (No details provided)                                 T4\                                                                                                                                                                                                                                                                               
                                                                                                       (No details provided)                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                         

  Buchbinder et al.\                *N* = 21     No details provided                                   No details provided      D       MIO                                                                                                                    Group 1: RT + unassisted exercise\                                        2, 4, 6, 8, 10 weeks                            The highest increase in MIO was reached in group 3
  1993 \[[@B48]\]                                                                                                                                                                                                                                              Group 2: RT + stacked tongue depressors combined + unassisted exercise\                                                   
                                                                                                                                                                                                                                                               Group 3: RT + TheraBite® system combined + unassisted exercise                                                            

                                                                                                                                                                                                                                                                                                                                                                                         

  Caudell et al.\                   *N* = 83     Nasal cavity = 3 (4%)\                                Tx-2 = 28 (34%)\         D       Videofluoroscopy\                                                                                                      Group 1: CRT (*n* = 70)\                                                  12 months                                       Mean dose to the larynx greater than 41 Gy and a receiving volume greater than 24% showed association with increased PEG dependency and aspiration
  2010 \[[@B49]\]                                Nasopharyngeal = 7 (8%)\                              T3-T4 = 55 (66%)                 PEG dependency                                                                                                         Group 2: RT (*n* = 13)                                                                                                    
                                                 Oral cavity = 1 (1%)\                                                                                                                                                                                                                                                                                                                   
                                                 Oropharyngeal = 44 (53%)\                                                                                                                                                                                                                                                                                                               
                                                 Hypopharyngeal = 6 (7%)\                                                                                                                                                                                                                                                                                                                
                                                 Laryngeal = 17 (21%)\                                                                                                                                                                                                                                                                                                                   
                                                 Unknown = 5 (6%)                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                         

  Christianen et al.\               *N* = 238    Nasopharyngeal = 8 (3%)\                              T1-T2 = 161 (68%)\       D       Grade of swallowing dysfunction according to the RTOG/EORTC Late Radiation Morbidity Scoring Criteria                  Group 1: conventional RT (*n* = 33)\                                      6, 12, 18, 24 months                            Patterns of swallowing dysfunction may be caused by radiobiological mechanisms of radiation induced damage and recovery. No group differences were found
  2015 \[[@B50]\]                                Oral cavity = 11 (5%)\                                T3-T4 = 77 (32%)                                                                                                                                        Group 2: accelerated RT (*n* = 155)\                                                                                      
                                                 Oropharyngeal = 71 (30%)\                                                                                                                                                                                     Group 3: CRT (*n* = 50)                                                                                                   
                                                 Hypopharyngeal = 12 (5%)\                                                                                                                                                                                                                                                                                                               
                                                 Laryngeal = 136 (57%)                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                         

  Cohen et al.\                     *N* = 53     Oral cavity = 14 (26%)\                               T0 = 3 (6%)\             D\      PSS-HN\                                                                                                                CRT                                                                       3, 6, 12, 18, 24, 36, 48, 60 months             Most patients returned to pretreatment function (QoL and performance) by 12 months
  2006 \[[@B74]\]                                Oropharyngeal = 11 (21%)\                             T1 = 3 (6%)\             QoL     Head and Neck RT Questionnaire (selected questions)\                                                                                                                                                                                             
                                                 Hypopharyngeal = 3 (6%)\                              T2 = 17 (32%)\                   FACT-H&N                                                                                                                                                                                                                                         
                                                 Laryngeal = 9 (17%)\                                  T3 = 30 (56%)                                                                                                                                                                                                                                                                     
                                                 Supraglottic = 13 (24%)\                                                                                                                                                                                                                                                                                                                
                                                 Unknown = 3 (6%)                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                         

  Dornfeld et al.\                  *N* = 27     Oral cavity = 1 (4%)\                                 Tx = 2 (7%)\             V\      Weight\                                                                                                                CRT                                                                       1 year                                          Speech, diet, and QoL outcomes showed an inverse relationship with the delivered radiation dose to the larynx
  2007 \[[@B22]\]                                Oropharyngeal = 16 (59%)\                             T1 = 6 (22%)\            D\      Type of diet\                                                                                                                                                                                                                                    
                                                 Hypopharyngeal = 1 (4%)\                              T2 = 7 (26%)\            QoL     Type of speech\                                                                                                                                                                                                                                  
                                                 Laryngeal = 6 (22%)\                                  T3 = 5 (19%)\                    Presence of PEG tube\                                                                                                                                                                                                                            
                                                 Unknown = 3 (11%)                                     T4 = 7 (26%)                     HNCI                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                         

  Dijkstra et al.\                  *N* = 29     Parotid = 4 (14%)\                                    No details provided      D       MIO                                                                                                                    RT                                                                        12--48 weeks                                    Increase in mouth opening was significantly less in the group of patients with trismus related to head and neck cancer and is difficult to treat with exercise therapy
  2007 \[[@B51]\]                                Maxilla = 4 (14%)\                                                                                                                                                                                                                                                                                                                      
                                                 Gingiva = 2 (7%)\                                                                                                                                                                                                                                                                                                                       
                                                 Floor of mouth = 3 (10%)\                                                                                                                                                                                                                                                                                                               
                                                 Trigonum retromolare = 4 (14%)\                                                                                                                                                                                                                                                                                                         
                                                 Oropharyngeal = 8 (27%)\                                                                                                                                                                                                                                                                                                                
                                                 Other localization = 4 (14%)                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                         

  Feng et al.\                      *N* = 36     Base of tongue = 19 (53%)\                            T1 = 2 (5%)\             D\      Videofluoroscopy\                                                                                                      CRT                                                                       3 months                                        Statistically significant dose-volume effect relationships for dysphagia and aspiration were found. Reducing the doses to the swallowing structures may improve swallowing
  2007 \[[@B52]\]                                Tonsil = 12 (33%)\                                    T2 = 11 (31%)\           QoL     Esophagogram\                                                                                                                                                                                                                                    
                                                 Nasopharyngeal = 5 (14%)                              T3 = 9 (25%)\                    HNQoL\                                                                                                                                                                                                                                           
                                                                                                       T4 = 14 (39%)                    UWQoL\                                                                                                                                                                                                                                           
                                                                                                                                        EORTC Late Radiation Morbidity Scale                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                         

  Feng et al.\                      *N* = 73     Base of tongue = 38 (52%)\                            T1 = 9 (12%)\            D       Videofluoroscopy\                                                                                                      CRT                                                                       3, 6, 12, 18, 24 months                         Long-term measures of swallowing were slightly worse than pretherapy measures
  2010 \[[@B53]\]                                Tonsil = 35 (48%)                                     T2 = 29 (40%)\                   UWQoL (swallowing question)\                                                                                                                                                                                                                     
                                                                                                       T3 = 17 (23%)\                   HNQoL (eating domain)\                                                                                                                                                                                                                           
                                                                                                       T4 = 18 (25%)                    Observer rated dysphagia                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                         

  Frowen et al.\                    *N* = 81     Base of tongue = 19 (24%)\                            T1 = 11 (14%)\           D       Videofluoroscopy                                                                                                       Group 1: CRT (*n* = 23)\                                                  3, 6 months                                     Swallowing in both groups was best at baseline; a decline at 3 months and an improvement at 6 months after therapy were shown. Baseline levels were not reached. Predictors for swallowing outcome were intoxications, tumor size, RT technique, and baseline level of swallowing. Patients who received conformal RT had a very low risk of penetration and aspiration of liquids by 6 months after treatment
  2010 \[[@B16]\]                                Soft palate = 2 (2%)\                                 T2 = 27 (33%)\                                                                                                                                          Group 2: CT (*n* = 58)                                                                                                    
                                                 Tonsil = 26 (32%)\                                    T3 = 31 (38%)\                                                                                                                                                                                                                                                                    
                                                 Supraglottic = 8 (10%)\                               T4 = 12 (15%)                                                                                                                                                                                                                                                                     
                                                 Hypopharyngeal = 8 (10%)\                                                                                                                                                                                                                                                                                                               
                                                 Laryngeal = 18 (22%)                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                         

  Haderlein et al.\                 *N* = 45     Oropharyngeal = 3 (7%)\                               T2 = 15 (33%)\           D\      PEG dependency\                                                                                                        CRT                                                                       3--6- month intervals                           Almost 50% of patients had deterioration of swallowing function after CRT
  2014 \[[@B54]\]                                Hypopharyngeal = 18 (40%)\                            T3 = 17 (38%)\           QoL     EORTC QLQ-C30                                                                                                                                                                                                                                    
                                                 Laryngeal = 24 (53%)\                                 T4 = 13 (29%)                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                         

  Hutcheson et al.\                 *N* = 47     Nasopharyngeal = 1 (2%)\                              T1 = 16 (34%)\           D       Videofluoroscopy\                                                                                                      Group 1: RT (*n* = 23)\                                                   6, 12, 24 months                                Two years after therapy, mild deterioration of swallowing without chronic aspiration was found
  2014 \[[@B55]\]                                Oral cavity = 1 (2%)\                                 T2 = 14 (30%)\                   PSS-HN\                                                                                                                Group 2: CRT (*n* = 23)\                                                                                                  
                                                 Oropharyngeal = 41 (88%)\                             T3 = 12 (25%)\                   MDADI                                                                                                                  Group 3: surgery (*n* = 1)                                                                                                
                                                 Hypopharyngeal = 2 (4%)\                              T4 = 5 (11%)                                                                                                                                                                                                                                                                      
                                                 Supraglottic = 2 (4%)                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                         

  Jacobi et al.\                    *N* = 34     Nasopharyngeal = 6 (18%)\                             T1 = 6 (18%)\            V       Speech analysis                                                                                                        CRT                                                                       10 weeks; 1 year                                Received dose to tongue and velopharynx were most relevant for speech and voice quality
  2016 \[[@B31]\]                                Oral cavity/oropharyngeal = 15 (44%)\                 T2 = 13 (38%)\                                                                                                                                                                                                                                                                    
                                                 Hypopharyngeal = 13 (38%)                             T3 = 11 (32%)\                                                                                                                                                                                                                                                                    
                                                                                                       T4 = 4 (12%)                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                         

  Karlsson et al.\                  *N* = 74     Laryngeal = 74 (100%)                                 T0 = 1 (1%)\             V\      EORTC QLQ-C30\                                                                                                         Group 1: CRT + voice rehabilitation (*n* = 37)\                           1, 6 months                                     Patients treated with voice rehabilitation experienced benefits of therapy on communication and HRQoL
  2015 \[[@B32]\]                                                                                      T1 = 44 (60%)\           QoL     EORTC QLQ-H&N35\                                                                                                       Group 2: CRT only (*n* = 37)                                                                                              
                                                                                                       T2 = 22 (30%)\                   S-SECEL                                                                                                                                                                                                                                          
                                                                                                       T3 = 6 (8%)\                                                                                                                                                                                                                                                                      
                                                                                                       T4 = 1 (1%)                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                         

  Karlsson et al.\                  *N* = 40     Laryngeal = 40 (100%)                                 Tis = 2 (5%)\            V\      EORTC QLQ-C30\                                                                                                         RT (1 subject received concomitant chemotherapy)                          1, 6, 12 months                                 One year after treatment most outcomes showed no significant improvements compared to baseline measurements
  2016 \[[@B33]\]                                                                                      T1 = 20 (50%)\           QoL     EORTC QLQ-H&N35\                                                                                                                                                                                                                                 
                                                                                                       T2 = 13 (33%)\                   S-SECEL\                                                                                                                                                                                                                                         
                                                                                                       T3 = 5 (12%)                     Perceptual and acoustic voice analysis                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                         

  Kazi et al.\                      *N* = 21     Hypopharyngeal = 8 (38%)\                             Stage III\               V       Voice analysis\                                                                                                        CRT                                                                       1, 6, 12 months                                 Patients treated with CRT had a better voice quality compared to patients after total laryngectomy
  2008 \[[@B34]\]                                Laryngeal = 10 (48%)\                                 Stage IV\                        Electroglottography                                                                                                                                                                                                                              
                                                 Supraglottic = 3 (14%)                                No details provided                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                         

  Kerr et al.\                      *N* = 200    Tongue base = 77 (38%)\                               T0-T1 = 42 (21%)\        V\      KPS\                                                                                                                   Group 1: 3DCRT (*n* = 83)\                                                3, 6, 12, 24 months                             IMRT showed better functional outcomes compared to 3DCRT, both 3--6 and 12--24 months after treatment
  2015 \[[@B35]\]                                Tonsil/soft palate = 123 (62%)                        T2 = 72 (36%)\           D       ECOG toxicity and response criteria scale\                                                                             Group 2: IMRT (*n* = 117)                                                                                                 
                                                                                                       T3 = 48 (24%)\                   PSS-HN\                                                                                                                                                                                                                                          
                                                                                                       T4 = 38 (19%)                    RBHOMS\                                                                                                                                                                                                                                          
                                                                                                                                        VHI-10\                                                                                                                                                                                                                                          
                                                                                                                                        Edmonton Self-Assessment Scale (Self-rated Xerostomia)                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                         

  Kotz et al.\                      *N* = 26     Nasopharyngeal = 1 (4%)\                              T2 = 1 (4%)\             D       PSS-HN (eating in public and normalcy of diet)\                                                                        Group 1: CRT + prophylactic swallowing therapy (*n* = 13)\                3, 6, 9, 12 months                              Prophylactic swallowing therapy improves swallowing at 3 and 6 months; later there were no group differences
  2012 \[[@B56]\]                                Tongue base = 11 (42%)\                               T3 = 5 (19%)\                    FOIS                                                                                                                   Group 2: CRT (*n* = 13)                                                                                                   
                                                 Tonsil = 11 (42%)\                                    T4 = 20 (77%)                                                                                                                                                                                                                                                                     
                                                 Oropharyngeal = 1 (4%)\                                                                                                                                                                                                                                                                                                                 
                                                 Glottic = 1 (4%)\                                                                                                                                                                                                                                                                                                                       
                                                 Unknown = 1 (4%)                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                         

  Kraaijenga et al.\                *N* = 22     Nasopharyngeal = 4 (18%)\                             T1 = 5 (23%)\            V\      Videofluoroscopy\                                                                                                      CRT                                                                       2, 6 years                                      Functional swallowing and voice problems at 6 years after treatment were minimal, possibly due to preventive swallowing rehabilitation programs
  2014 \[[@B36]\]                                Oral cavity/\                                         T2 = 9 (41%)\            D\      Acoustic analysis\                                                                                                                                                                                                                               
                                                 oropharyngeal = 10 (46%)\                             T3 = 7 (32%)\            QoL     Presence of feeding tube\                                                                                                                                                                                                                        
                                                 Hypopharyngeal/\                                      T4 = 1 (4%)                      FOIS\                                                                                                                                                                                                                                            
                                                 laryngeal = 8 (36%)                                                                    Pain (VAS)\                                                                                                                                                                                                                                      
                                                                                                                                        Trismus\                                                                                                                                                                                                                                         
                                                                                                                                        QoL aspects (based on EORTC QLQ-C30 and EORTC QLQ-H&N35)\                                                                                                                                                                                        
                                                                                                                                        SWAL-QoL\                                                                                                                                                                                                                                        
                                                                                                                                        VHI                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                         

  Kumar et al.\                     *N* = 46     Tonsil = 19 (41%)\                                    T0 = 2 (4%)\             D       Videofluoroscopy                                                                                                       CRT                                                                       From \<6 to \>18 months                         Aspiration and penetration were associated with dose and volume delivered to the floor of mouth muscles
  2014 \[[@B57]\]                                Base of tongue = 22 (47%)\                            T1 = 15 (33%)\                                                                                                                                                                                                                                                                    
                                                 Pharyngeal wall = 3 (7%)\                             T2 = 14 (30%)\                                                                                                                                                                                                                                                                    
                                                 Unknown = 2 (5%)                                      T3 = 12 (26%)\                                                                                                                                                                                                                                                                    
                                                                                                       T4 = 3 (7%)                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                         

  Lazarus et al.\                   *N* = 29     Nasopharyngeal = 3 (10%)\                             Stage I = 2 (7%)\        D\      Tongue strength, jaw ROM, and tongue ROM\                                                                              CRT                                                                       3, 6 months\                                    Patients performed worse in oral outcomes, performance status, and QoL after treatment
  2014 \[[@B38]\]                                Oropharyngeal = 18 (63%)\                             Stage II = 1 (4%)\       V\      Saliva weight\                                                                                                                                                                                                                                   
                                                 Pharyngeal = 1 (3%)\                                  Stage III = 5 (17%)\     QoL     Eating Assessment Tool\                                                                                                                                                                                                                          
                                                 Hypopharyngeal = 1 (3%)\                              Stage IVa = 21 (72%)             MDADI\                                                                                                                                                                                                                                           
                                                 Laryngeal = 5 (18%)\                                                                   Speech Handicap Index\                                                                                                                                                                                                                           
                                                 Unknown primary = 1 (3%)                                                               EORTC QLQ-H&N35\                                                                                                                                                                                                                                 
                                                                                                                                        PSS-HN (normalcy of diet, eating in public, and understandability of speech)\                                                                                                                                                                    
                                                                                                                                        KPS                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                         

  List et al.\                      *N* = 64     Nasopharyngeal = 1 (2%)\                              Stage III = 4 (6%)\      D\      KPS\                                                                                                                   CRT                                                                       1, 3, 6, 9, 12 months                           Decline of QoL and functional aspects resolved 1 year after treatment; however, oral intake stayed restricted
  1999 \[[@B75]\]                                Oral cavity = 6 (9%)\                                 Stage IV = 60 (94%)      QoL     PSS-HN\                                                                                                                                                                                                                                          
                                                 Oropharyngeal = 34 (53%)\                                                              McMaster University Head and Neck RT Questionnaire (selected questions)\                                                                                                                                                                         
                                                 Hypopharyngeal = 10 (16%)\                                                             FACT-H&N                                                                                                                                                                                                                                         
                                                 Laryngeal = 9 (14%)\                                                                                                                                                                                                                                                                                                                    
                                                 Other = 4 (6%)                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                         

  McLaughlin et al.\                *N* = 91     Nasopharyngeal = 9 (10%)\                             Stage II = 1 (1%)\       D       Weight loss\                                                                                                           CRT                                                                       6, 12 months                                    Patients treated with CRT could be managed without nutritional support via G-tube. Dysphagia at baseline and advanced tumor stage are associated with increased risk of longer G-tube dependency
  2010 \[[@B58]\]                                Oral cavity = 19 (21%)\                               Stage III = 21 (23%)\            Aspiration\                                                                                                                                                                                                                                      
                                                 Oropharyngeal = 32 (35%)\                             Stage IV = 69 (76%)              Overall nutritional status\                                                                                                                                                                                                                      
                                                 Hypopharyngeal = 7 (8%)\                                                               Duration G-tube placement\                                                                                                                                                                                                                       
                                                 Laryngeal = 12 (13%)\                                                                  Treatment-related complications                                                                                                                                                                                                                  
                                                 Unknown = 4 (4%)\                                                                                                                                                                                                                                                                                                                       
                                                 Other = 8 (9%)                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                         

  Mittal et al.\                    *N* = 39     Nasopharyngeal = 4 (10%)\                             Stage III = 5 (13%)\     D\      Videofluoroscopy\                                                                                                      Group 1: CRT with TDC (*n* = 18)\                                         3 months                                        Patients treated with TDC had better oral intake, swallowing function, and articulation
  2001 \[[@B37]\]                                Oropharyngeal = 17 (44%)\                             Stage IV = 34 (87%)      V       Saliva production\                                                                                                     Group 2: CRT without TDC (*n* = 21)                                                                                       
                                                 Hypopharyngeal = 7 (18%)\                                                              PSS-HN\                                                                                                                                                                                                                                          
                                                 Laryngeal = 5 (13%)\                                                                   FACT-H&N\                                                                                                                                                                                                                                        
                                                 Unknown = 6 (15%)                                                                      Fisher-Logemann Test of Articulation Competence                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                         

  Murry et al. 1998 \[[@B59]\]      *N* = 37     Oropharyngeal = 19 (52%)\                             T3\                      D       HNRQ\                                                                                                                  CRT                                                                       6 months                                        During treatment QoL and swallowing function decreased acutely and significantly. Six months after therapy QoL exceeded pretreatment level. Recovery was site-specific: oropharyngeal tumor patients had poorest outcome, whereas hypopharyngeal tumor patients showed most rapid recovery. Physical recovery followed psychosocial recovery. Organ preservation treatment may improve swallowing after treatment
                                                 Hypopharyngeal = 6 (16%)\                             T4\                              Questionnaire on swallowing                                                                                                                                                                                                                      
                                                 Laryngeal = 12 (32%)                                  (No details provided)                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                         

  Niedzielska et al.\               *N* = 45     Laryngeal = 45 (100%)                                 T1 = 24 (53%)\           V       Videolaryngostroboscopy\                                                                                               RT                                                                        1--3 years                                      All irradiated patients showed reduced vibration of the vocal cords. Except for some of the acoustic parameters, most data were comparable to a healthy control group (*N* = 24)
  2010 \[[@B39]\]                                                                                      T2 = 21 (47%)                    Acoustic analysis                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                         

  Nourissat et al.\                 *N* = 535    Oral cavity = 63 (12%)\                               T1 = 329 (61%)\          D\      Weight\                                                                                                                RT                                                                        Direct posttherapy                              The occurrence of adverse effects of RT appeared to be one of the main reasons for weight loss. Correlations were found between genetic factors associated with the adverse effects of cancer treatments
  2010 \[[@B60]\]                                Oropharyngeal = 17 (3%)\                              T2 = 206 (39%)           QoL     KPS\                                                                                                                                                                                                                                             
                                                 Hypopharyngeal = 8 (1%)\                                                               EORTC QLQ-C30\                                                                                                                                                                                                                                   
                                                 Supraglottic = 100 (19%)\                                                              Structured general questionnaire                                                                                                                                                                                                                 
                                                 Glottic = 347 (65%)                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                         

  Ottoson et al.\                   *N* = 101    Oral cavity = 20 (20%)\                               T1 = 11 (10%)\           D       Videofluoroscopy\                                                                                                      RT                                                                        5 years                                         Dysphagia with aspiration was related to unintentional weight loss and a lower BMI
  2014 \[[@B61]\]                                Oropharyngeal = 62 (61%)\                             T2 = 16 (16%)\                   BMI                                                                                                                                                                                                                                              
                                                 Hypopharyngeal = 8 (8%)\                              T3 = 28 (28%)\                                                                                                                                                                                                                                                                    
                                                 Laryngeal = 11 (11%)                                  T4 = 46 (46%)                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                         

  Pauli et al.\                     *N* = 75     Sinus, nose = 6 (8%)\                                 T0 = 5 (7%)\             D\      MIO\                                                                                                                   Group 1: surgery (*n* = 8)\                                               3, 6, 12 months                                 Trismus was a major side effect of the treatment of head and neck cancer and deteriorates HRQoL
  2013 \[[@B62]\]                                Salivary gland = 10 (13%)\                            T1 = 13 (17%)\           QoL     Patient-reported outcome\                                                                                              Group 2: surgery + RT (*n* = 15)\                                                                                         
                                                 Gingiva, buccal = 6 (8%)\                             T2 = 29 (39%)\                   Gothenburg Trismus Questionnaire\                                                                                      Group 3: surgery + CRT (*n* = 6)\                                                                                         
                                                 Tongue, floor of mouth = 15 (20%)\                    T3 = 9 (12%)\                    EORTC QLQ-C30\                                                                                                         Group 4: RT (*n* = 16)\                                                                                                   
                                                 Tonsil = 24 (32%)\                                    T4 = 18 (24%)\                   EORTC QLQ-H&N35\                                                                                                       Group 5: CRT (*n* = 29)\                                                                                                  
                                                 Base of tongue, oropharyngeal = 11 (15%)\             Unknown = 1 (1%)                 HADS                                                                                                                   Group 6: no treatment (*n* = 1)                                                                                           
                                                 Other = 3 (4%)                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                         

  Pauloski et al.\                  *N* = 170    Nasopharyngeal = 8 (5%)\                              Stage IV = 122 (72%)\    D       Videofluoroscopy\                                                                                                      Group 1: CRT (*n* = 147)\                                                 1, 3, 6, 12 months                              In both groups limitations in oral intake and diet after cancer treatment were significantly related to reduced laryngeal elevation and reduced cricopharyngeal opening due to treatment
  2006 \[[@B63]\]                                Oral cavity = 15 (9%)\                                Other = 48 (28%)                 Oral intake                                                                                                            Group 2: RT (*n* = 22)\                                                                                                   
                                                 Oropharyngeal = 80 (47%)\                                                                                                                                                                                     Unknown (*n* = 1)                                                                                                         
                                                 Hypopharyngeal = 14 (8%)\                                                                                                                                                                                                                                                                                                               
                                                 Laryngeal = 42 (25%)\                                                                                                                                                                                                                                                                                                                   
                                                 Unknown = 11 (6%)                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                         

  Rademaker et al.\                 *N* = 255    Nasopharyngeal = 13 (5%)\                             Stage II = 16 (6%)\      D       Percentage of oral intake\                                                                                             CRT                                                                       1, 3, 6, 12 months                              Eating ability decreased during treatment and improved 12 months after treatment to near pretreatment levels
  2003 \[[@B64]\]                                Oral cavity = 25 (10%)\                               Stage III = 48 (19%)\            Food consistencies                                                                                                                                                                                                                               
                                                 Oropharyngeal = 118 (46%) Hypopharyngeal = 22 (9%)\   Stage IV = 187 (73%)\                                                                                                                                                                                                                                                             
                                                 Laryngeal = 59 (23%)\                                 Unknown = 4 (2%)                                                                                                                                                                                                                                                                  
                                                 Unknown = 18 (7%)                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                         

  Remmelts et al.\                  *N* = 248    Glottic = 248 (100%)                                  Tis = 26 (10%)\          V       VHI (physical subscale)\                                                                                               Group 1: RT (*n* = 159)\                                                  12 months                                       VHI scores were comparable for both groups. Regarding laryngeal preservation surgery is the treatment of first choice
  2013 \[[@B40]\]                                                                                      T1a = 103 (42%)\                 5-item questionnaire                                                                                                   Group 2: laser surgery (*n* = 89)                                                                                         
                                                                                                       T1b = 42 (17%)\                                                                                                                                                                                                                                                                   
                                                                                                       T2 = 77 (31%)                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                         

  Salama et al.\                    *N* = 95     Nasopharyngeal = 4 (4%)\                              Tx = 7 (7%)\             D       Videofluoroscopy\                                                                                                      CRT                                                                       1-2 months                                      Improvement of swallowing ability compared to baseline was associated with advanced tumor stage
  2008 \[[@B65]\]                                Oral cavity = 8 (9%)\                                 T1 = 15 (16%)\                   SPS                                                                                                                                                                                                                                              
                                                 Oropharyngeal = 49 (52%)\                             T2 = 19 (20%)\                                                                                                                                                                                                                                                                    
                                                 Hypopharyngeal = 5 (5%)\                              T3 = 16 (17%)\                                                                                                                                                                                                                                                                    
                                                 Laryngeal = 22 (23%)\                                 T4 = 38 (40%)                                                                                                                                                                                                                                                                     
                                                 Other = 7 (7%)                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                         

  Sanguineti et al.\                *N* = 124    Base of tongue = 54 (43%)\                            T0 = 8 (6%)\             V       CTCAE\                                                                                                                 Group 1: CRT (*n* = 108)\                                                 3, 6, 12, 18, 24, 36, 48, 60 months             Mild voice changes were common and strictly correlated to mean dose to larynx and should be kept under 50 Gy
  2014 \[[@B23]\]                                Soft palate = 2 (2%)\                                 T1 = 37 (30%)\                   FACT-HN (items HN4 and HN10)                                                                                           Group 2: RT (*n* = 16)                                                                                                    
                                                 Tonsil = 59 (48%)\                                    T2 = 49 (40%)\                                                                                                                                                                                                                                                                    
                                                 Pharyngeal wall = 1 (1%)\                             T3 = 14 (11%)\                                                                                                                                                                                                                                                                    
                                                 Unknown = 8 (6%)                                      T4 = 16 (13%)                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                         

  Scrimger et al.\                  *N* = 47     Nasopharyngeal = 10 (21%)\                            T0 = 2 (4%)\             D\      Mouth saliva flow\                                                                                                     Group 1: RT (*n* = 5)\                                                    3, 6, 12 months                                 Nonsurgery resulted in better QoL questionnaire scores compared to surgery. Patients with good saliva production did not exhibit better QoL after RT than patients with less saliva production
  2007 \[[@B66]\]                                Oral cavity = 20 (43%)\                               T1 = 7 (15%)\            QoL     UW-QoL\                                                                                                                Group 2: CRT (*n* = 12)\                                                                                                  
                                                 Oropharyngeal = 9 (19%)\                              T2 = 20 (42%)\                   RTOG late-toxicity scale\                                                                                              Group 3: surgery + RT (*n* = 30)                                                                                          
                                                 Hypopharyngeal/\                                      T3 = 12 (26%)\                   XQoL                                                                                                                                                                                                                                             
                                                 laryngeal = 6 (13%)\                                  T4 = 6 (13%)                                                                                                                                                                                                                                                                      
                                                 Unknown primary = 2 (4%)                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                         

  Spector et al.\                   *N* = 659    Glottic = 659 (100%)                                  T1 = 659 (100%)          V       Voice preservation                                                                                                     Group 1: low-dose RT (*n* = 90)\                                          5 years                                         Groups 2--4 had similar unaided laryngeal voice preservation rates; however group 1 had significant lower unaided laryngeal voice preservation
  1999 \[[@B41]\]                                                                                                                                                                                                                                              Group 2: high-dose RT (*n* = 104)\                                                                                        
                                                                                                                                                                                                                                                               Group 3: conservation surgery (*n* = 404)\                                                                                
                                                                                                                                                                                                                                                               Group 4: endoscopic resection (*n* = 61)                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                         

  Starmer et al.\                   *N* = 71     Oropharyngeal = 71 (100%)                             T1 = 24 (34%)\           D       Videofluoroscopy\                                                                                                      Group 1: CRT (*n* = 65)\                                                  1--18 months                                    Patients undergoing nonsurgical treatment for oropharyngeal tumors were at risk for posttreatment dysphagia
  2014 \[[@B67]\]                                                                                      T2 = 19 (27%)\                   FOIS                                                                                                                   Group 2: RT (*n* = 6)                                                                                                     
                                                                                                       T3 = 13 (18%)\                                                                                                                                                                                                                                                                    
                                                                                                       T4 = 12 (17%)\                                                                                                                                                                                                                                                                    
                                                                                                       Unknown = 3 (4%)                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                         

  Stenson et al. 2010 \[[@B68]\]    *N* = 111    Buccal = 4 (3%)\                                      T1 = 9 (8%)\             D       Videofluoroscopy\                                                                                                      Group 1: CRT (*n* = 84)\                                                  2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36 months   Ninety-two percent of all patients were able to maintain weight via oral route.\
                                                 Alveolus/gingivae = 7 (6%)\                           T2 = 15 (14%)\                   SPS                                                                                                                    Group 2: surgery + CRT (*n* = 27)                                                                                         Both groups showed comparable overall survival. Ninety-two percent of all patients had a sufficient oral intake
                                                 Floor of mouth = 32 (29%)\                            T3 = 20 (18%)\                                                                                                                                                                                                                                                                    
                                                 Tongue = 50 (45%)\                                    T4 = 67 (60%)                                                                                                                                                                                                                                                                     
                                                 Palate/oral cavity NOS = 4 (4%)   \                                                                                                                                                                                                                                                                                                     
                                                 Trigonum retromolare = 13 (12%)\                                                                                                                                                                                                                                                                                                        
                                                 Unknown = 1 (1%)                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                         

  Strigari et al.\                  *N* = 63     Nasopharyngeal = 44 (70%)\                            T1-T2 = 17 (23%)\        D       Saliva flow\                                                                                                           RT                                                                        3, 6, 12, 18, 24 months                         The mean score on the xerostomia related questionnaire increased (worsened) after RT and decreased (improved) over time in all patients
  2010 \[[@B69]\]                                Floor of mouth/oral cavity = 2 (3%)\                  T3-T4 = 46 (73%)                 Xerostomia related questionnaires\                                                                                                                                                                                                               
                                                 Oropharyngeal = 11 (17%)\                                                              RTOG late-toxicity scale                                                                                                                                                                                                                         
                                                 Hypopharyngeal = 4 (7%)\                                                                                                                                                                                                                                                                                                                
                                                 Unknown primary = 2 (3%)                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                         

  Tuomi et al.\                     *N* = 67     Supraglottic = 13 (19%)\                              Tis = 2 (3%)\            V\      Acoustic analysis\                                                                                                     RT                                                                        1 month                                         Patients treated for supraglottic tumors experienced more problems in eating and swallowing prior to therapy compared to glottic tumors and demonstrated significant HRQoL reduction after treatment. In contrast, glottic tumors presented with inferior voice quality
  2015 \[[@B42]\]                                Glottic = 54 (81%)                                    T1 = 41 (61%)\           D\      EORTC QLQ-C30\                                                                                                                                                                                                                                   
                                                                                                       T2 = 17 (25%)\           QoL     EORTC QLQ-H&N35\                                                                                                                                                                                                                                 
                                                                                                       T3 = 6 (9%)\                     S-SECEL                                                                                                                                                                                                                                          
                                                                                                       T4 = 1 (2%)                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                         

  Urdaniz et al.\                   *N* = 60     Paranasal sinuses = 3 (5%)\                           T2 = 2 (3%)\             QoL     EORTC QLQ-C30\                                                                                                         Group 1: hyperfractionated concomitant boost RT + cisplatin (*n* = 30)\   1 month                                         QoL in both groups was relatively good. QoL improved in the follow-up period
  2005 \[[@B77]\]                                Nasopharyngeal = 3 (5%)\                              T3 = 20 (33%)\                   EORTC QLQ-H&N35                                                                                                        Group 2: hyperfractionated conventional RT + cisplatin (*n* = 30)                                                         
                                                 Oral cavity = 2 (3%)\                                 T4 = 38 (64%)                                                                                                                                                                                                                                                                     
                                                 Oropharyngeal = 25 (42%)\                                                                                                                                                                                                                                                                                                               
                                                 Hypopharyngeal = 9 (15%)\                                                                                                                                                                                                                                                                                                               
                                                 Laryngeal = 18 (30%)                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                         

  Vainshtein et al.\                *N* = 40     Base of tongue = 18 (45%)\                            T1 = 8 (20%)\            D\      HNQoL\                                                                                                                 CRT                                                                       1, 3, 6, 12, 18, 24 months                      At 6.5 years after therapy patients showed a stable or improved HRQoL in most domains comparable with baseline and 2 years after therapy
  2015 \[[@B70]\]                                Tonsil = 22 (55%)                                     T2 = 20 (50%)\           QoL     UWQoL\                                                                                                                                                                                                                                           
                                                                                                       T3 = 8 (20%)\                    XQoL                                                                                                                                                                                                                                             
                                                                                                       T4 = 4 (10%)                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                         

  van der Molen et al.\             *N* = 49     Nasopharyngeal = 7 (14%)\                             T1 = 8 (16%)\            D       Videofluoroscopy\                                                                                                      Group 1: standard rehabilitation (*n* = 28)\                              10 weeks                                        (Preventive) rehabilitation\
  2011 \[[@B76]\]                                Oral cavity/\                                         T2 = 15 (31%)\                   MIO\                                                                                                                   Group 2: experimental rehabilitation (*n* = 27)                                                                           in head and neck cancer patients was feasible and improved functional outcomes after therapy
                                                 oropharyngeal = 24 (49%)\                             T3 = 19 (39%)\                   BMI\                                                                                                                                                                                                                                             
                                                 Hypopharyngeal/\                                      T4 = 7 (14%)                     FOIS\                                                                                                                                                                                                                                            
                                                 laryngeal = 18 (37%)                                                                   VAS pain                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                         

  van der Molen et al.\             *N* = 55     Nonlaryngeal = 36 (65%)\                              T1 = 8 (15%)\            V\      Acoustic analysis\                                                                                                     CRT                                                                       10 weeks; 1 year                                CRT effects 10 weeks after therapy were worse than 1 year after therapy, and both were worse than baseline
  2012 \[[@B44]\]                                Laryngeal = 19 (35%)                                  T2 = 15 (27%)\           QoL     Study-specific QoL questionnaire                                                                                                                                                                                                                 
                                                                                                       T3 = 21 (38%)\                                                                                                                                                                                                                                                                    
                                                                                                       T4 = 11 (20%)                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                         

  van der Molen et al.\             *N* = 55     Nasopharyngeal = 7 (13%)\                             T1 = 8 (15%)\            D       Videofluoroscopy\                                                                                                      CRT                                                                       10 weeks; 1 year                                A correlation between doses and structures was found for dysphagia and trismus
  2013 \[[@B71]\]                                Oral cavity/\                                         T2 = 15 (27%)\                   MIO\                                                                                                                                                                                                                                             
                                                 oropharyngeal = 29 (53%)\                             T3 = 21 (38%)\                   Study-specific structured questionnaire                                                                                                                                                                                                          
                                                 Hypopharyngeal/\                                      T4 = 11 (20%)                                                                                                                                                                                                                                                                     
                                                 laryngeal = 19 (34%)                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                         

  Verdonck-de Leeuw et al.\         *N* = 60     Glottic = 60 (100%)                                   T1 = 60 (100%)           V       Videolaryngostroboscopy Voice quality rating\                                                                          RT                                                                        0.5--10 years                                   Voice and its characteristics improved after treatment but did not reach pretreatment levels in half of the patients
  1999 \[[@B43]\]                                                                                                                       Self-rating of vocal performance and quality                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                         

  Verdonck-de Leeuw et al.\         *N* = 164    Oral/oropharyngeal = 95 (58%)\                        No details provided      QoL     EORTC QLQ-C30\                                                                                                         CRT                                                                       6 weeks; 6, 12, 18, 24 months                   Significant difference in HRQoL between survivors and nonsurvivors in favor of survivors was found
  2014 \[[@B79]\]                                Hypopharyngeal/\                                                                       EORTC QLQ-H&N35                                                                                                                                                                                                                                  
                                                 laryngeal = 69 (42%)                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                         

  Vlacich et al.\                   *N* = 141    Sinus/nasal cavity = 2 (1%)\                          Stage III = 42 (30%)\    D       PEG requirement                                                                                                        CRT                                                                       12 months                                       IMRT dose to the inferior constrictor correlated with persistent dysphagia requiring prolonged PEG use
  2014 \[[@B72]\]                                Nasopharyngeal = 12 (9%)\                             Stage IVa = 81 (57%)\                                                                                                                                                                                                                                                             
                                                 Oral cavity = 5 (4%)\                                 Stage IVb = 18 (13%)                                                                                                                                                                                                                                                              
                                                 Oropharyngeal = 82 (58%)\                                                                                                                                                                                                                                                                                                               
                                                 Hypopharyngeal = 6 (4%)\                                                                                                                                                                                                                                                                                                                
                                                 Laryngeal = 30 (21%)\                                                                                                                                                                                                                                                                                                                   
                                                 Unknown = 4 (3%)                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                         

  Wilson et al.\                    *N* = 167    Nasopharyngeal = 5 (3%)\                              T1 = 37 (22%)\           D\      MDADI\                                                                                                                 Group 1: CRT (*n* = 104)\                                                 3, 6, 12 months                                 HRQoL deteriorated significantly after treatment. Little improvement may be expected 3 to 12 months after treatment
  2011 \[[@B73]\]                                Oropharyngeal = 66 (39%)\                             T2 = 37 (22%)\           QoL     UWQoL                                                                                                                  Group 2: RT (*n* = 63)                                                                                                    
                                                 Hypopharyngeal = 21 (13%)\                            T3 = 37 (22%)\                                                                                                                                                                                                                                                                    
                                                 Laryngeal = 63 (38%)\                                 T4 = 44 (27%)\                                                                                                                                                                                                                                                                    
                                                 Unknown primary = 12 (7%)                             Unknown = 12 (7%)                                                                                                                                                                                                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

3DCRT: 3D conformal radiotherapy; BMI: body mass index; CRT: chemoradiotherapy; CTCAE: common terminology criteria for adverse events; D: digestive tract; ECOG: Eastern Cooperative Oncology Group; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; EORTC QLQ-H&N35: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Module Head and Neck Cancer; FACT-HN: functional assessment of cancer therapy-head and neck; FOIS: functional oral intake scale; GRBAS: grade, roughness, breathiness, asthenia, strain scale; HADS: hospital anxiety and depression scale; HNCI: head and neck cancer inventory; HNQoL: head and neck quality of life; HNRQ: head and neck radiotherapy questionnaire; HRQoL: health-related quality of life; IMRT: intensity-modulated radiation therapy; KPS: Karnofsky performance status scale; LENT/SOMA: late effects normal tissue-subjective, objective, management, analytic scales; MDADI: MD Anderson dysphagia inventory; MIO: maximum incisal opening; NOS: not otherwise specified; PEG: percutaneous endoscopic gastrostomy; PSS-HN: performance status scale for head and neck cancer patients; QoL: quality of life; RBHOMS: Royal Brisbane Hospital outcome measure for swallowing; ROM: range of motion; RT: radiotherapy; RTOG: Radiation Therapy Oncology Group; S-SECEL: Swedish version of the self-evaluation of communication experiences after laryngeal cancer; SPS: swallowing performance status scale; TDC: tissue/dose compensation; UWQoL: University of Washington Quality of Life Questionnaire; V: voice and/or speech; VAS: visual analog scale; VHI: voice handicap index; VHI-10: voice handicap index-10; VR-QoL: voice-related quality of life; XQoL: xerostomia questionnaire.

###### 

Overview of speech pathology interventions aimed at addressing problems in dysphagia, speech, voice, and trismus (*n* = 14).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference               Topic                    General description of intervention and treatment intensity/duration                                                                                                                  Description of specific exercises                                                                                                                                                                                                                                  Conclusions specific to therapy
  ----------------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Agarwal et al.\         Voice                    All patients received counseling and voice therapy by a trained speech pathologist\                                                                                                   No description of exercises provided                                                                                                                                                                                                                               Forty-seven of 50 patients showed compliance to the therapy. No specific conclusions of influence of provided therapy on primary outcomes described
  2009 \[[@B26]\]                                  No specific data provided on treatment frequency/intensity                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Akst et al.\            Swallowing               Swallowing evaluation and intervention when clinically indicated                                                                                                                      No description of exercises provided                                                                                                                                                                                                                               No specific conclusions of influence of provided therapy on primary outcomes described
  2004 \[[@B46]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Buchbinder et al.\      Trismus                  Six to 10 exercise sessions per day for a 10-week period                                                                                                                              Group 1: unassisted exercises: reach maximum MIO and closing, jaw motion to left, right, and protrusively\                                                                                                                                                         The first four weeks no differences between groups were found. After week 4 minimal improvements in groups 1 and 2 were found and group 3 still improved. The highest increment in MIO was reached in group 3
  1993 \[[@B48]\]                                                                                                                                                                                                                        Group 2: unassisted exercises: reach maximum MIO and closing, jaw motion to left, right, and protrusively. Stacked tongue depressors, to mechanically increase MIO (5 × 30 seconds per session)\                                                                   
                                                                                                                                                                                                                                         Group 3: unassisted exercises: reach maximum MIO and closing, jaw motion to left, right, and protrusively. Combined with the TheraBite System (5 × 30 seconds per session)                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Dijkstra et al.\        Trismus                  Physical therapy for trismus, median of 4 sessions                                                                                                                                    Physical therapy consisting of\                                                                                                                                                                                                                                    MIO increases significantly after physical therapy. History of HNC decreases the effect of physical therapy, compared to other trismus patients
  2007 \[[@B51]\]                                                                                                                                                                                                                        (i) Active range of motion\                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                         (ii) Hold and relax\                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                         (iii) Manual stretching\                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                         (iv) Joint distraction\                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                         Following therapeutic tools are used in described cohort:\                                                                                                                                                                                                         
                                                                                                                                                                                                                                         (i) Rubber plugs\                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                         (ii) Tong blades\                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                         (iii) Dynamic bite opener\                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                         (iv) TheraBite System                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Frowen et al.\          Swallowing               All patients were seen by a speech pathologist as an aspect of regular care                                                                                                           No description of exercises provided                                                                                                                                                                                                                               No specific conclusions of influence of provided therapy on primary outcomes described
  2010 \[[@B16]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Hutcheson et al.\       Swallowing               All patients received prophylactic swallowing therapy to avoid nothing by mouth periods during treatment\                                                                             Targeted swallowing exercises                                                                                                                                                                                                                                      No specific conclusions of influence of provided therapy on primary outcomes described
  2014 \[[@B55]\]                                  No specific data provided on treatment frequency/intensity                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Karlsson et al.\        Voice                    Group 1: voice therapy group received 10 × 30-minute sessions over 10 weeks\                                                                                                          Group 1: voice therapy consisting of relaxation, respiration, posture, and phonation exercises\                                                                                                                                                                    Patients treated with voice therapy experienced greater improvements compared to patients that only received vocal hygiene advice. Group 1 showed a significant better functional communication and HRQoL
  2015 \[[@B32]\]                                  Group 2: vocal hygiene group: 1 session for vocal hygiene advice                                                                                                                      Group 2: vocal hygiene advice                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Kotz et al.\            Swallowing               Group 1: weekly treatment by speech pathologist and daily 3 × 10 home sessions of exercises. Group 2: swallowing assessment and treatment if necessary after treatment                Group 1: prophylactic swallowing therapy consisting of effortful swallow, tongue base retraction exercises, super supraglottic swallow, and the Mendelssohn maneuver\                                                                                              Prophylactic swallowing therapy improves swallowing at 3 and 6 months; later there were no group differences found
  2012 \[[@B56]\]                                                                                                                                                                                                                        Group 2: control group only receive symptomatic dysphagia treatment                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Kraaijenga et al.\      Swallowing and voice     Daily practice from the start of the treatment until 1 year after treatment                                                                                                           Two combined groups: TheraBite System and standard logopedic swallowing exercises (the same cohort as van der Molen et al. 2011 \[[@B76]\])                                                                                                                        Minimal voice and swallowing difficulties were found 60 months after treatment in patients treated with prophylactic swallowing exercises
  2014 \[[@B36]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Sanguineti et al.\      Voice                    75.8% of the patients received speech therapy. No therapy was provided to 30 patients\                                                                                                No description of exercises provided                                                                                                                                                                                                                               No specific conclusions of influence of provided therapy on primary outcomes described
  2014 \[[@B23]\]                                  No specific data provided on treatment frequency/intensity                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Starmer et al.\         Swallowing               Patients received prophylactic swallowing and trismus exercises                                                                                                                       No description of exercises provided                                                                                                                                                                                                                               No specific conclusions of influence of provided therapy on primary outcomes described
  2014 \[[@B67]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  van der Molen et al.\   Swallowing               Patients received instructions in advance of their oncological treatment. Three times daily exercises                                                                                 Group 1: range-of-motion exercises and three strengthening exercises, that is, the effortful swallow, the Masako maneuver, and the super supraglottic swallow. Stretch holding for 10--30 seconds at a point of mild discomfort\                                   Similar outcomes in both groups were found. Preventive rehabilitation can improve early posttreatment functional outcomes
  2011 \[[@B76]\]                                                                                                                                                                                                                        Group 2: stretch of the mouth using the TheraBite System and a strengthening exercise: swallowing with the tongue elevated to the palate while maintaining mouth opening at 50% of its maximum. Stretch holding for 10--30 seconds at a point of mild discomfort   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  van der Molen et al.\   Voice                    No specific speech or voice therapy                                                                                                                                                   N/A                                                                                                                                                                                                                                                                N/A
  2012 \[[@B44]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  van der Molen et al.\   Swallowing and trismus   Study was aimed at describing dose-effect relationships in two treatment groups described in earlier study. References to other published study where treatment regime is described   Group 1: standard exercises\                                                                                                                                                                                                                                       Any possible difference between the two included treatment groups is not described, nor possible influence of the respective treatments
  2013 \[[@B71]\]                                                                                                                                                                                                                        Group 2: experimental exercises                                                                                                                                                                                                                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HNC: head and neck cancer; HRQoL: health-related quality of life; MIO: maximum incisal opening; ROM: range of motion.
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